Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS)

Historical Holders from Q2 2020 to Q3 2025

Symbol
KROS on Nasdaq
CUSIP
492327101
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
30.3M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
35.3M
Holdings value
$558M
% of all portfolios
0.004%
Grand Portfolio weight change
0%
Number of holders
146
Number of buys
79
Number of sells
-52
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Madison Avenue Partners, LP 6.4% $32M 2.61M Madison Avenue Partners, LP May 7, 2025
VANGUARD GROUP INC 6.32% $31.4M 2.57M The Vanguard Group Mar 31, 2025
TANG CAPITAL MANAGEMENT LLC 7.9% $38.3M 2.42M TANG CAPITAL MANAGEMENT, LLC Oct 15, 2025
ExodusPoint Capital Management, LP 6.3% $28.7M 1.91M ExodusPoint Capital Management, LP Nov 10, 2025
D. E. SHAW & CO, L.P. 5.1% $24.5M 1.55M D. E. Shaw & Co., L.P. Oct 20, 2025
ALKEON CAPITAL MANAGEMENT LLC 2.7% $13.5M 1.1M Alkeon Capital Management LLC Dec 31, 2024
FMR LLC 1.7% $8.62M 704K FMR LLC Jan 31, 2025
JPMORGAN CHASE & CO 0.2% -102% $1.39M -$30.3M 114K -95.6% JPMORGAN CHASE & CO. Apr 30, 2025

Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 35.3M $558M -$6.43M $15.82 146
2025 Q2 35.9M $480M +$53.9M $13.35 136
2025 Q1 32.8M $334M -$102M $10.19 154
2024 Q4 36.7M $582M -$99.6M $15.83 158
2024 Q3 34.9M $2.03B +$197M $58.07 163
2024 Q2 31.5M $1.44B -$1.91M $45.70 149
2024 Q1 31.4M $2.08B +$419M $66.20 144
2023 Q4 49.8K $1.99M -$1.39M $39.76 3
2023 Q3 22.8M $727M +$8.07M $31.88 103
2023 Q2 22.4M $900M +$13.1M $40.18 119
2023 Q1 22M $937M +$93.6M $42.70 127
2022 Q4 19.7M $948M +$89.1M $48.02 119
2022 Q3 17.5M $659M +$33.2M $37.62 100
2022 Q2 17.2M $476M +$7.91M $27.63 96
2022 Q1 15.6M $847M +$4.51M $54.38 96
2021 Q4 15.7M $918M +$68.3M $58.51 92
2021 Q3 13.8M $545M -$17.1M $39.56 86
2021 Q2 12.9M $547M -$44.3M $42.47 77
2021 Q1 14.4M $886M -$122M $61.55 81
2020 Q4 15.8M $1.11B +$300M $70.54 78
2020 Q3 11.5M $442M +$34M $38.57 47
2020 Q2 10.9M $410M +$409M $37.51 51